GLP-1 Prescribing Lags Among Adults With Schizophrenia & Diabetes

From 2018 through 2024, adults with serious mental illness (SMI) were more likely than adults without SMI to receive a prescription for a glucagon-like peptide-1 Adults with diabetes and schizophrenia were less likely to receive glucagon-like peptide-1 (GLP-1) receptor agonist prescriptions than adults with diabetes who did not have serious mental illness (SMI). In 2018, 3.4% of adults with diabetes and schizophrenia received a GLP-1 prescription, compared with 4.5% of adults with diabetes without SMI. By 2024, GLP-1 prescribing had increased substantially for both groups, reaching 19.4% among adults with . . .